Type 2 diabetes and viral infection; cause and effect of disease

Tamara Turk Wensveen, Dora Gašparini, Dario Rahelić, Felix M Wensveen, Tamara Turk Wensveen, Dora Gašparini, Dario Rahelić, Felix M Wensveen

Abstract

The recent pandemic of COVID-19 has made abundantly clear that Type 2 diabetes (T2D) increases the risk of more frequent and more severe viral infections. At the same time, pro-inflammatory cytokines of an anti-viral Type-I profile promote insulin resistance and form a risk factor for development of T2D. What this illustrates is that there is a reciprocal, detrimental interaction between the immune and endocrine system in the context of T2D. Why these two systems would interact at all long remained unclear. Recent findings indicate that transient changes in systemic metabolism are induced by the immune system as a strategy against viral infection. In people with T2D, this system fails, thereby negatively impacting the antiviral immune response. In addition, immune-mediated changes in systemic metabolism upon infection may aggravate glycemic control in T2D. In this review, we will discuss recent literature that sheds more light on how T2D impairs immune responses to viral infection and how virus-induced activation of the immune system increases risk of development of T2D.

Keywords: Antidiabetic drugs; COVID-19; Corona virus; Diabetes; Diabetes mellitus type 2; Immune defects; Immune system; Immunometabolism; Infection; Insulin resistance; T2D; Viral infection.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2020 Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
Negative impacts of T2D on immunological control of viral infection.
Fig. 2
Fig. 2
Pro-diabetic effects of viral infection. Viral infection activates a Type-I immune response, resulting in the production of cytokines such as TNF, IFNγ and IL-6. These induce transient insulin resistance in muscle and liver. The pancreas compensates IR through increased secretion of insulin, which directly promotes the antiviral immune system. In obesity, cytokine-induced IR can contribute to the formation of IR. In addition, several viruses infect the pancreas, which negatively impacts its ability to produce insulin. This may also contribute to loss of pancreatic β-cell function.

References

    1. Muller L.M., Gorter K.J., Hak E., Goudzwaard W.L., Schellevis F.G., Hoepelman A.I., et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–288.
    1. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020:e3319.
    1. Apicella M., Campopiano M.C., Mantuano M., Mazoni L., Coppelli A., Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020
    1. Roberts B.W., Cech I. Association of type 2 diabetes mellitus and seroprevalence for cytomegalovirus. South Med J. 2005;98:686–692.
    1. O'Neill L.A., Kishton R.J., Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16:553–565.
    1. Kotas M.E., Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell. 2015;160:816–827.
    1. Sestan M., Marinovic S., Kavazovic I., Cekinovic D., Wueest S., Turk Wensveen T., et al. Virus-induced interferon-gamma causes insulin resistance in skeletal muscle and derails glycemic control in obesity. Immunity. 2018;49(164–77)
    1. Wensveen F.M., Sestan M., Turk Wensveen T., Polic B. 'Beauty and the beast' in infection: How immune-endocrine interactions regulate systemic metabolism in the context of infection. Eur J Immunol. 2019;49:982–995.
    1. Johnson A.R., Milner J.J., Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev. 2012;249:218–238.
    1. Pearson-Stuttard J., Blundell S., Harris T., Cook D.G., Critchley J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol. 2016;4:148–158.
    1. Emerging Risk Factors C., Seshasai S.R., Kaptoge S., Thompson A., Di Angelantonio E., Gao P., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–841.
    1. Stoeckle M., Kaech C., Trampuz A., Zimmerli W. The role of diabetes mellitus in patients with bloodstream infections. Swiss Med Wkly. 2008;138:512–519.
    1. Gupta S., Koirala J., Khardori R., Khardori N. Infections in diabetes mellitus and hyperglycemia. Infect Dis Clin North Am. 2007;21(617–38):vii.
    1. Jeon C.Y., Murray M.B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5
    1. Association A.D. Standards of medical care in diabets - 2017. Diabetes Care. 2017;40:S1–132.
    1. Muehlenbein M.P., Hirschtick J.L., Bonner J.Z., Swartz A.M. Toward quantifying the usage costs of human immunity: Altered metabolic rates and hormone levels during acute immune activation in men. Am J Hum Biol. 2010;22:546–556.
    1. Straub R.H., Cutolo M., Buttgereit F., Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med. 2010;267:543–560.
    1. Van Acker H.H., Anguille S., Willemen Y., Van den Bergh J.M., Berneman Z.N., Lion E., et al. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J Hematol Oncol. 2016;9:101.
    1. Paz-Filho G., Mastronardi C., Wong M.L., Licinio J. Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J Endocrinol Metab. 2012;16:S549–S555.
    1. Yu X., Park B.H., Wang M.Y., Wang Z.V., Unger R.H. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci U S A. 2008;105:14070–14075.
    1. Denroche H.C., Levi J., Wideman R.D., Sequeira R.M., Huynh F.K., Covey S.D., et al. Leptin therapy reverses hyperglycemia in mice with streptozotocin-induced diabetes, independent of hepatic leptin signaling. Diabetes. 2011;60:1414–1423.
    1. Moon H.S., Matarese G., Brennan A.M., Chamberland J.P., Liu X., Fiorenza C.G., et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes. 2011;60:1647–1656.
    1. Villanueva E.C., Myers M.G., Jr. Leptin receptor signaling and the regulation of mammalian physiology. Int J Obes (Lond) 2008;32(Suppl 7):S8–S12.
    1. Tian Z., Sun R., Wei H., Gao B. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun. 2002;298:297–302.
    1. Maurya R., Bhattacharya P., Dey R., Nakhasi H.L. Leptin functions in infectious diseases. Front Immunol. 2018;9:2741.
    1. La Cava A., Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4:371–379.
    1. Wieland C.W., Florquin S., Chan E.D., Leemans J.C., Weijer S., Verbon A., et al. Pulmonary Mycobacterium tuberculosis infection in leptin-deficient ob/ob mice. Int Immunol. 2005;17:1399–1408.
    1. Gerriets V.A., Danzaki K., Kishton R.J., Eisner W., Nichols A.G., Saucillo D.C., et al. Leptin directly promotes T-cell glycolytic metabolism to drive effector T-cell differentiation in a mouse model of autoimmunity. Eur J Immunol. 2016;46:1970–1983.
    1. Wolf A.M., Wolf D., Rumpold H., Enrich B., Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323:630–635.
    1. Wilk S., Scheibenbogen C., Bauer S., Jenke A., Rother M., Guerreiro M., et al. Adiponectin is a negative regulator of antigen-activated T cells. Eur J Immunol. 2011;41:2323–2332.
    1. Tsai S., Clemente-Casares X., Zhou A.C., Lei H., Ahn J.J., Chan Y.T., et al. Insulin receptor-mediated stimulation boosts T cell immunity during inflammation and infection. Cell Metab. 2018;28(922–34)
    1. Frauwirth K.A., Riley J.L., Harris M.H., Parry R.V., Rathmell J.C., Plas D.R., et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16:769–777.
    1. Kornum J.B., Thomsen R.W., Riis A., Lervang H.H., Schonheyder H.C., Sorensen H.T. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31:1541–1545.
    1. Simonsen J.R., Harjutsalo V., Jarvinen A., Kirveskari J., Forsblom C., Groop P.H., et al. Bacterial infections in patients with type 1 diabetes: a 14-year follow-up study. BMJ Open Diabetes Res Care. 2015;3
    1. Ayelign B., Negash M., Genetu M., Wondmagegn T., Shibabaw T. Immunological impacts of diabetes on the susceptibility of mycobacterium tuberculosis. J Immunol Res. 2019;2019:6196532.
    1. Kumar N.P., Sridhar R., Nair D., Banurekha V.V., Nutman T.B., Babu S. Type 2 diabetes mellitus is associated with altered CD8(+) T and natural killer cell function in pulmonary tuberculosis. Immunology. 2015;144:677–686.
    1. Turina M., Fry D.E., Polk H.C., Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med. 2005;33:1624–1633.
    1. Wong S.L., Demers M., Martinod K., Gallant M., Wang Y., Goldfine A.B., et al. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat Med. 2015;21:815–819.
    1. Reinhold D., Ansorge S., Schleicher E.D. Elevated glucose levels stimulate transforming growth factor-beta 1 (TGF-beta 1), suppress interleukin IL-2, IL-6 and IL-10 production and DNA synthesis in peripheral blood mononuclear cells. Horm Metab Res. 1996;28:267–270.
    1. Geerlings S.E., Brouwer E.C., Gaastra W., Verhoef J., Hoepelman A.I.M. Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol. 1999;48:535–539.
    1. Geerlings S.E., Hoepelman A.I. Immune dysfunction in patients with diabetes mellitus (DM) FEMS Immunol Med Microbiol. 1999;26:259–265.
    1. Greiner E.F., Guppy M., Brand K. Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J Biol Chem. 1994;269:31484–31490.
    1. Gubser P.M., Bantug G.R., Razik L., Fischer M., Dimeloe S., Hoenger G., et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat Immunol. 2013;14:1064–1072.
    1. van der Windt G.J., Everts B., Chang C.H., Curtis J.D., Freitas T.C., Amiel E., et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity. 2012;36:68–78.
    1. Guzik T.J., Cosentino F. Epigenetics and Immunometabolism in Diabetes and Aging. Antioxid Redox Signal. 2018;29:257–274.
    1. Landini M.P. Early enhanced glucose uptake in human cytomegalovirus-infected cells. J Gen Virol. 1984;65(Pt 7):1229–1232.
    1. Yu Y., Maguire T.G., Alwine J.C. Human cytomegalovirus activates glucose transporter 4 expression to increase glucose uptake during infection. J Virol. 2011;85:1573–1580.
    1. Codo A.C., Davanzo G.G., Monteiro L.B., de Souza G.F., Muraro S.P., Virgilio-da-Silva J.V., et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/glycolysis-dependent axis. Cell Metab. 2020;32(437–46)
    1. Jacobs S.R., Herman C.E., Maciver N.J., Wofford J.A., Wieman H.L., Hammen J.J., et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol. 2008;180:4476–4486.
    1. Duncan C.J., Mohamad S.M., Young D.F., Skelton A.J., Leahy T.R., Munday D.C., et al. Human IFNAR2 deficiency: Lessons for antiviral immunity. Sci Transl Med. 2015 7:307ra154.
    1. Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–724.
    1. Hui S., Ghergurovich J.M., Morscher R.J., Jang C., Teng X., Lu W., et al. Glucose feeds the TCA cycle via circulating lactate. Nature. 2017;551:115–118.
    1. Chen Y.D., Varasteh B.B., Reaven G.M. Plasma lactate concentration in obesity and type 2 diabetes. Diabete Metab. 1993;19:348–354.
    1. Mongraw-Chaffin M.L., Matsushita K., Brancati F.L., Astor B.C., Coresh J., Crawford S.O., et al. Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study. PLoS ONE. 2012;7
    1. Saisho Y. Importance of beta cell function for the treatment of type 2 diabetes. J Clin Med. 2014;3:923–943.
    1. Bandaru P., Shankar A. Association between plasma leptin levels and diabetes mellitus. Metab Syndr Relat Disord. 2011;9:19–23.
    1. Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., Moller R., et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(1036–45)
    1. Musilli C., Paccosi S., Pala L., Gerlini G., Ledda F., Mugelli A., et al. Characterization of circulating and monocyte-derived dendritic cells in obese and diabetic patients. Mol Immunol. 2011;49:234–238.
    1. Hannibal T.D., Schmidt-Christensen A., Nilsson J., Fransen-Pettersson N., Hansen L., Holmberg D. Deficiency in plasmacytoid dendritic cells and type I interferon signalling prevents diet-induced obesity and insulin resistance in mice. Diabetologia. 2017;60:2033–2041.
    1. Pinto R.A., Arredondo S.M., Bono M.R., Gaggero A.A., Diaz P.V. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol. Pediatrics. 2006;117:e878–e886.
    1. Yoo S.G., Han K.D., Lee K.H., La Y., Kwon D.E., Han S.H. Impact of cytomegalovirus disease on new-onset type 2 diabetes mellitus: population-based matched case-control cohort study. Diabetes Metab J. 2019;43:815–829.
    1. Esser N., Legrand-Poels S., Piette J., Scheen A.J., Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141–150.
    1. Wensveen F.M., Jelencic V., Valentic S., Sestan M., Wensveen T.T., Theurich S., et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol. 2015;16:376–385.
    1. Wensveen F.M., Valentic S., Sestan M., Turk Wensveen T., Polic B. Interactions between adipose tissue and the immune system in health and malnutrition. Semin Immunol. 2015;27:322–333.
    1. Chi Y., Ge Y., Wu B., Zhang W., Wu T., Wen T., et al. Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China. J Infect Dis. 2020;222:746–754.
    1. Wang Q., Fang P., He R., Li M., Yu H., Zhou L., et al. O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5. Sci Adv. 2020 6:eaaz7086.
    1. Randeria S.N., Thomson G.J.A., Nell T.A., Roberts T., Pretorius E. Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc Diabetol. 2019;18:72.
    1. Gupta R., Hussain A., Misra A. Diabetes and COVID-19: evidence, current status and unanswered research questions. Eur J Clin Nutr. 2020;74:864–870.
    1. Abiko Y., Selimovic D. The mechanism of protracted wound healing on oral mucosa in diabetes. Review Bosn J Basic Med Sci. 2010;10:186–191.
    1. American D.A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S13–S27.
    1. Greene J.A.K.G. Insulin resistance due to infection in diabetes mellitus in man. JAMA. 1943;121:173–176.
    1. Fernandez-Real J.M., Lopez-Bermejo A., Vendrell J., Ferri M.J., Recasens M., Ricart W. Burden of infection and insulin resistance in healthy middle-aged men. Diabetes Care. 2006;29:1058–1064.
    1. Yki-Jarvinen H., Sammalkorpi K., Koivisto V.A., Nikkila E.A. Severity, duration, and mechanisms of insulin resistance during acute infections. J Clin Endocrinol Metab. 1989;69:317–323.
    1. Kim K.H., Hong S.P., Kim K., Park M.J., Kim K.J., Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun. 2007;355:883–888.
    1. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065–1067.
    1. Salmon D., Bani-Sadr F., Loko M.A., Stitou H., Gervais A., Durant J., et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. J Hepatol. 2012;56:862–868.
    1. Rubino F., Amiel S.A., Zimmet P., Alberti G., Bornstein S., Eckel R.H., et al. New-onset diabetes in covid-19. N Engl J Med. 2020;383:789–790.
    1. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.
    1. Wensveen F.M., Valentic S., Sestan M., Turk Wensveen T., Polic B. The, “Big Bang” in obese fat: Events initiating obesity-induced adipose tissue inflammation. Eur J Immunol. 2015;45:2446–2456.
    1. Schultz O., Oberhauser F., Saech J., Rubbert-Roth A., Hahn M., Krone W., et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE. 2010;5
    1. Kiortsis D.N., Mavridis A.K., Vasakos S., Nikas S.N., Drosos A.A. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005;64:765–766.
    1. Malozowski S., Sahlroot J.T. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;357:302–303. author reply 3.
    1. Dregan A., Charlton J., Chowienczyk P., Gulliford M.C. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014;130:837–844.
    1. Hotamisligil G.S., Murray D.L., Choy L.N., Spiegelman B.M. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A. 1994;91:4854–4858.
    1. Jager J., Gremeaux T., Cormont M., Le Marchand-Brustel Y., Tanti J.F. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148:241–251.
    1. Lebovitz H.E. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl. 2003;18–27
    1. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–184.
    1. Gumbs A.A., Modlin I.M., Ballantyne G.H. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg. 2005;15:462–473.
    1. Vafaeimanesh J., Parham M., Seyyedmajidi M., Bagherzadeh M. Helicobacter pylori infection and insulin resistance in diabetic and nondiabetic population. ScientificWorldJournal. 2014;2014
    1. Tabak A.G., Jokela M., Akbaraly T.N., Brunner E.J., Kivimaki M., Witte D.R. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215–2221.
    1. Filippi C.M., von Herrath M.G. Viral trigger for type 1 diabetes: pros and cons. Diabetes. 2008;57:2863–2871.
    1. Liu F., Long X., Zhang B., Zhang W., Chen X., Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020;18(2128–30)
    1. Shen B., Yi X., Sun Y., Bi X., Du J., Zhang C., et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182(59–72)
    1. Dror E., Dalmas E., Meier D.T., Wueest S., Thevenet J., Thienel C., et al. Postprandial macrophage-derived IL-1beta stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol. 2017;18:283–292.
    1. Verity R., Okell L.C., Dorigatti I., Winskill P., Whittaker C., Imai N., et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669–677.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Hojyo S., Uchida M., Tanaka K., Hasebe R., Tanaka Y., Murakami M., et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40:37.
    1. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020
    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
    1. Zhu L., She Z.G., Cheng X., Qin J.J., Zhang X.J., Cai J., et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(1068–77)
    1. Apicella M., Campopiano M.C., Mantuano M., Mazoni L., Coppelli A., Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8:782–792.
    1. Holman N., Knighton P., Kar P., O'Keefe J., Curley M., Weaver A., et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8:823–833.
    1. Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323:1574–1581.
    1. Barron E., Bakhai C., Kar P., Weaver A., Bradley D., Ismail H., et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813–822.
    1. Cariou B., Hadjadj S., Wargny M., Pichelin M., Al-Salameh A., Allix I., et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63:1500–1515.
    1. Wu L., Girgis C.M., Cheung N.W. COVID-19 and diabetes: Insulin requirements parallel illness severity in critically unwell patients. Clin Endocrinol (Oxf) 2020
    1. Gianchandani R., Esfandiari N.H., Ang L., Iyengar J., Knotts S., Choksi P., et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes. 2020;69:2048–2053.
    1. Tucey T.M., Verma J., Harrison P.F., Snelgrove S.L., Lo T.L., Scherer A.K., et al. Glucose homeostasis is important for immune cell viability during candida challenge and host survival of systemic fungal infection. Cell Metab. 2018;27(988–1006)
    1. Teng R.J., Wu T.J., Ho M.M. Mumps infection complicated by transient hyperinsulinemic hypoglycemia. Pediatr Infect Dis J. 1997;16:416–417.
    1. Freyberg Z., Harvill E.T. Pathogen manipulation of host metabolism: A common strategy for immune evasion. PLoS Pathog. 2017;13
    1. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517–1526.
    1. Larsen C.M., Faulenbach M., Vaag A., Ehses J.A., Donath M.Y., Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32:1663–1668.
    1. Interleukin 1 Genetics C. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol 2015;3:243-53
    1. Gupta-Ganguli M., Cox K., Means B., Gerling I., Solomon S.S. Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes? Diabetes Care. 2011;34
    1. Berry R., Watson G.M., Jonjic S., Degli-Esposti M.A., Rossjohn J. Modulation of innate and adaptive immunity by cytomegaloviruses. Nat Rev Immunol. 2020;20:113–127.
    1. Wang Z., Du Z., Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract. 2020;164
    1. Ceriello A., Standl E., Catrinoiu D., Itzhak B., Lalic N.M., Rahelic D., et al. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. Diabetes Care. 2020;43:1427–1432.
    1. Chang CH, Wang JL, Wu LC, Chuang LM, Lin HH. Diabetes, glycemic control, and risk of infection morbidity and mortality: a cohort study. Open Forum Infect Dis. 2019;6:ofz358.
    1. Mor A., Petersen I., Sorensen H.T., Thomsen R.W. Metformin and other glucose-lowering drug initiation and rates of community-based antibiotic use and hospital-treated infections in patients with type 2 diabetes: a Danish nationwide population-based cohort study. BMJ Open. 2016;6
    1. Ekstrom N., Schioler L., Svensson A.M., Eeg-Olofsson K., Miao Jonasson J., Zethelius B., et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open. 2012;2
    1. Garnett J.P., Baker E.H., Naik S., Lindsay J.A., Knight G.M., Gill S., et al. Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose. Thorax. 2013;68:835–845.
    1. Duncan A.I., Koch C.G., Xu M., Manlapaz M., Batdorf B., Pitas G., et al. Recent metformin ingestion does not increase in-hospital morbidity or mortality after cardiac surgery. Anesth Analg. 2007;104:42–50.
    1. Shih C.J., Wu Y.L., Chao P.W., Kuo S.C., Yang C.Y., Li S.Y., et al. Association between use of oral anti-diabetic drugs and the risk of sepsis: a nested case-control study. Sci Rep. 2015;5:15260.
    1. Filippatos T.D., Panagiotopoulou T.V., Elisaf M.S. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11:202–230.
    1. Sainsbury C., Wang J., Gokhale K., Acosta-Mena D., Dhalla S., Byne N., et al. Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study. Diabetes Obes Metab. 2020
    1. Schuiveling M., Vazirpanah N., Radstake T., Zimmermann M., Broen J.C.A. Metformin, A new era for an old drug in the treatment of immune mediated disease? Curr Drug Targets. 2018;19:945–959.
    1. Pearce E.L., Walsh M.C., Cejas P.J., Harms G.M., Shen H., Wang L.S., et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460:103–107.
    1. Hulme K.D., Gallo L.A., Short K.R. Influenza virus and glycemic variability in diabetes: a killer combination? Front Microbiol. 2017;8:861.
    1. Investigators N.-S.-S., Finfer S., Chittock D.R., Su S.Y., Blair D., Foster D., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–1297.
    1. McClave S.A., Taylor B.E., Martindale R.G., Warren M.M., Johnson D.R., Braunschweig C., et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: society of critical care medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) JPEN J Parenter Enteral Nutr. 2016;40:159–211.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere